ID

Inga Deakin

Health and Life Sciences VC at Molten Ventures

London, England

Invests in

  • Min Investment:

    $100,000.00
  • Max Investment:

    $5,000,000.00
  • Target Investment:

    $1,500,000.00

Skills

Venture Capital
Lifesciences
Biotechnology
Business Development
Pharmaceutical Industry
Medical Devices
Life Sciences
Technology Transfer
Molecular Biology
Science
Entrepreneurship
Intellectual Property
Business Planning
Healthcare
Commercialization
Market Analysis

Education

Work Experience

  • Principal

    2020

    Investing in Healthtech, Life Sciences, TechBio in UK and Europe

2023

  • Director

    2023

  • Director

    2023

2023

  • Director

    2023

2021

  • Director

    2021

2019 - 2020

  • Entrepreneur In Residence

    2019 - 2020

    Helping academic enterpreneurs commercialise products that they invent across specialising in medical devices and healthtech. EIR in Biomedical Engineering at Duke, consistently rated in the top 3 BME departments in the US. Mentor in Residence at Office of Licensing and Ventures, with 17 start-ups in 2020.

2017 - 2019

  • Chief of Staff

    2017 - 2019

    Liquid biopsy molecular diagnostics company in oncology. Based in the US coordinating operations as Chief of Staff as the company gained regulatory approval and initial sales into the US healthcare system.

Touchstone Innovations

2017 - 2018

  • Principal

    2017 - 2018

    In January 2017, the venture investment teams at Imperial Innovations changed name to Touchstone Innovations, which was acquired by IP Group PLC, a FTSE250 company, a few months later. Identifying, building and investing in life science companies - therapeutics, medical devices, diagnostics and healthcare companies including digital health.

2014 - 2017

  • Non Executive Director

    2015 - 2017

    Puridify, a bioprocessing company, was acquired by GE Healthcare in November 2017 https://www.touchstoneinnovations.com/news-room/2017/nov/28/portfolio-company-puridify-acquired-ge-healthcare/

  • Board Observer

    2014 - 2015

2016 - 2017

  • Board Observer

    2016 - 2017

    Haemophilia drug development company. Innovations co-led a £14m Series A in 2016 with Medicxi to fund development of SerpinPC to treat haemophilia. In October 2019, the company started its PhaseI/II study. http://apcintex.com/